Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rATG versus basiliximab induction in Chinese DCD kidney transplant recipients
ChiCTR1800017266Phase 4Recruiting
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Jul 2018
- Modality
- Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of antithymocyte globulin and basiliximab in kidney transplant (3 arms), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: Acute rejection rate. Started Jul 2018; status: recruiting.
02
Drugs
antithymocyte globulinbasiliximab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on ChiCTR1800017266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017266.